{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:17:02Z","timestamp":1772165822734,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015741","name":"Kids Brain Health Network","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100015741","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fetal Alcohol Spectrum Disorder (FASD) is characterized by physical and neurological abnormalities resulting from prenatal alcohol exposure. Though diagnosis may help improve patient outcomes, the diagnostic process can be costly. Subsequently, screening children suspected of FASD prior to diagnostic testing has been suggested, to avoid administering testing to children who are unlikely to receive a diagnosis. The present study set out to assess the cost-effectiveness of currently recommended FASD screening tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The screenings tools evaluated were chosen from Children\u2019s Healthcare Canada\u2019s National Screening Toolkit for Children and Youth Identified and Potentially Affected by FASD and include meconium testing of fatty acid ethyl esters (meconium testing) and the neurobehavioral screening tool (NST). An economic model was constructed to assess cost-effectiveness. One-way and probabilistic sensitivity analyses were conducted to assess the robustness of findings. Costs reflect 2017 Canadian dollars and the perspective is the public healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both screening tools evaluated resulted in reduced costs and fewer diagnosed years of life than a no screening strategy in which all children suspected of FASD receive diagnostic testing. The model predicts that screening newborns with meconium testing results in a reduced cost of $89,186 per 100 individuals screened and 38 fewer diagnosed years of life by age 18, corresponding to an incremental cost-effectiveness ratio (ICER) of $2359. Screening children with the NST resulted in a reduced cost of $183,895 per 100 individuals screened and 77 fewer diagnosed years of life by age 18, corresponding to an ICER of $2390.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings suggest that screening is associated with less use of healthcare recourses but also fewer years of life with an FASD diagnosis over a no screening strategy. Since diagnosis can be key to children receiving timely and appropriate health and educational services, cost-savings must be weighed against the fewer years of life with a diagnosis associated with screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-019-8110-5","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T13:02:42Z","timestamp":1577451762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The cost-effectiveness of screening tools used in the diagnosis of fetal alcohol spectrum disorder: a modelled analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-7978","authenticated-orcid":false,"given":"Patrick","family":"Berrigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"issue":"3","key":"8110_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1503\/cmaj.141593","volume":"188","author":"JL Cook","year":"2016","unstructured":"Cook JL, Green CR, Lilley CM, Anderson SM, Baldwin ME, Chudley AE, et al. Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. CMAJ. 2016;188(3):191\u20137. https:\/\/doi.org\/10.1503\/cmaj.141593.","journal-title":"CMAJ"},{"issue":"22","key":"8110_CR2","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1001\/jama.290.22.2996","volume":"290","author":"RJ Sokol","year":"2003","unstructured":"Sokol RJ, Delaney-Black V, Nordstrom B. Fetal alcohol spectrum disorder. JAMA. 2003;290(22):2996\u20139. https:\/\/doi.org\/10.1001\/jama.290.22.2996.","journal-title":"JAMA"},{"key":"8110_CR3","volume-title":"World Health Organization International Study on the Prevalence of Fetal Alcohol Spectrum Disorder (FASD) Canadian Component","author":"S Popova","year":"2018","unstructured":"Popova S, Lange S, Chudley AE, Reynolds JN, Rehm J. World Health Organization International Study on the Prevalence of Fetal Alcohol Spectrum Disorder (FASD) Canadian Component. 2018. www.camh.ca Accessed 3 Apr 2019."},{"issue":"5","key":"8110_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.17269\/cjph.102.2718","volume":"102","author":"S Popova","year":"2011","unstructured":"Popova S, Lange S, Bekmuradov D, Mihic A, Rehm J. Fetal alcohol spectrum disorder prevalence estimates in correctional systems: a systematic literature review. Can J Public Health. 2011;102(5):336\u201340. https:\/\/doi.org\/10.17269\/cjph.102.2718.","journal-title":"Can J Public Health"},{"issue":"3","key":"8110_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ddrr.66","volume":"15","author":"DK Fast","year":"2009","unstructured":"Fast DK, Conry J. Fetal alcohol spectrum disorders and the criminal justice system. Dev Disabil Res Rev. 2009;15(3):250\u20137. https:\/\/doi.org\/10.1002\/ddrr.66.","journal-title":"Dev Disabil Res Rev"},{"issue":"4","key":"8110_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/bdra.20445","volume":"82","author":"L Burd","year":"2008","unstructured":"Burd L, Klug MG, Bueling R, Martsolf J, Olson M, Kerbeshian J. Mortality rates in subjects with fetal alcohol spectrum disorders and their siblings. Birth Defects Research Part A. Clin Mol Teratol. 2008 Apr;82(4):217\u201323. https:\/\/doi.org\/10.1002\/bdra.20445.","journal-title":"Clin Mol Teratol"},{"issue":"1","key":"8110_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jpepsy\/jsj029","volume":"31","author":"KK Howell","year":"2005","unstructured":"Howell KK, Lynch ME, Platzman KA, Smith GH, Coles CD. Prenatal alcohol exposure and ability, academic achievement, and school functioning in adolescence: A longitudinal follow-up. J Pediatr Psychol. 2005;31(1):116\u201326. https:\/\/doi.org\/10.1093\/jpepsy\/jsj029.","journal-title":"J Pediatr Psychol"},{"issue":"3","key":"8110_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/alcalc\/agv117","volume":"51","author":"S Popova","year":"2015","unstructured":"Popova S, Lange S, Burd L, Rehm J. The economic burden of fetal alcohol spectrum disorder in Canada in 2013. Alcohol Alcohol. 2015;51(3):367\u201375. https:\/\/doi.org\/10.1093\/alcalc\/agv117.","journal-title":"Alcohol Alcohol"},{"issue":"12","key":"8110_CR9","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/acer.12903","volume":"39","author":"N Reid","year":"2015","unstructured":"Reid N, Dawe S, Shelton D, Harnett P, Warner J, Armstrong E, et al. Systematic review of fetal alcohol spectrum disorder interventions across the life span. Alcohol Clin Exp Res. 2015;39(12):2283\u201395. https:\/\/doi.org\/10.1111\/acer.12903.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"8110_CR10","first-page":"e27","volume":"22","author":"A Hanlon-Dearman","year":"2015","unstructured":"Hanlon-Dearman A, Green CR, Andrew G, LeBlanc N, Cook JL. Anticipatory guidance for children and adolescents with fetal alcohol spectrum disorder (FASD): practice points for primary health care providers. J Popul Ther Clin Pharmacol. 2015;22(1):e27\u201356.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"2","key":"8110_CR11","first-page":"e193","volume":"20","author":"N Thanh","year":"2013","unstructured":"Thanh N, Moffatt J, Jacobs P, Chuck A, Jonsson E. Potential impacts of the Alberta fetal alcohol spectrum disorder service networks on secondary disabilities: a cost-benefit analysis. J Popul Ther Clin Pharmacol. 2013;20(2):e193\u2013200.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"4","key":"8110_CR12","doi-asserted-by":"publisher","first-page":"e60434","DOI":"10.1371\/journal.pone.0060434","volume":"8","author":"S Popova","year":"2013","unstructured":"Popova S, Lange S, Burd L, Chudley AE, Clarren SK, Rehm J. Cost of fetal alcohol spectrum disorder diagnosis in Canada. PLoS One. 2013;8(4):e60434. https:\/\/doi.org\/10.1371\/journal.pone.0060434.","journal-title":"PLoS One"},{"key":"8110_CR13","volume-title":"National Screening Tool Kit for Children and Youth Identified and Potentially Affected by FASD","author":"The Canadian Association of Paediatric Health Centres (CAPHC)","year":"2019","unstructured":"The Canadian Association of Paediatric Health Centres (CAPHC). National Screening Tool Kit for Children and Youth Identified and Potentially Affected by FASD. 2019. https:\/\/ken.childrenshealthcarecanada.ca\/xwiki\/bin\/view\/FASDScreeningToolkit\/National+Screening+Tool+Kit+for+Children+and+Youth+Identified+and+Potentially+Affected+by+FASD Accessed 18 June 2018."},{"issue":"1","key":"8110_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10488-014-0537-5","volume":"42","author":"NX Thanh","year":"2015","unstructured":"Thanh NX, Jonsson E, Moffatt J, Dennett L, Chuck AW, Birchard S. An economic evaluation of the parent\u2013child assistance program for preventing fetal alcohol Spectrum disorder in Alberta, Canada. Adm Policy Ment Health. 2015;42(1):10\u20138. https:\/\/doi.org\/10.1007\/s10488-014-0537-5.","journal-title":"Adm Policy Ment Health"},{"issue":"4","key":"8110_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.15288\/jsad.2008.69.510","volume":"69","author":"RB Hopkins","year":"2008","unstructured":"Hopkins RB, Paradis J, Roshankar T, Bowen J, Tarride JE, Blackhouse G, et al. Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis. J Stud Alcohol Drugs. 2008;69(4):510\u20139. https:\/\/doi.org\/10.15288\/jsad.2008.69.510.","journal-title":"J Stud Alcohol Drugs"},{"key":"8110_CR16","unstructured":"Koren G, Chudley A, Loock C, MacLeod SM, Rosales T, Rosenbaum C, et al. Screening and referral to identify children at risk for FASD: Search for new methods 2006\u20132013. J Popul Ther Clin Pharmacol. 2014;21(2):e260\u2013e265."},{"issue":"3","key":"8110_CR17","doi-asserted-by":"publisher","first-page":"e20160517","DOI":"10.1542\/peds.2016-0517","volume":"138","author":"C McQuire","year":"2016","unstructured":"McQuire C, Paranjothy S, Hurt L, Mann M, Farewell D, Kemp A. Objective measures of prenatal alcohol exposure: a systematic review. Pediatrics. 2016;138(3):e20160517. https:\/\/doi.org\/10.1542\/peds.2016-0517.","journal-title":"Pediatrics"},{"issue":"1","key":"8110_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40359-017-0191-2","volume":"5","author":"S Lange","year":"2017","unstructured":"Lange S, Rovet J, Rehm J, Popova S. Neurodevelopmental profile of fetal alcohol spectrum disorder: a systematic review. BMC Psychol. 2017;5(1):22. https:\/\/doi.org\/10.1186\/s40359-017-0191-2.","journal-title":"BMC Psychol"},{"key":"8110_CR19","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","author":"Canadian Agency for Drugs and Technologies in Health (CADTH)","year":"2017","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada. 4th ed; 2017. https:\/\/www.cadth.ca\/dv\/guidelines-economic-evaluation-health-technologies-canada-4th-edition Accessed 17 Sept 2018","edition":"4"},{"key":"8110_CR20","doi-asserted-by":"crossref","unstructured":"Lamsal R, Finlay B, Whitehurst DGT, Zwicker JD. Generic preference-based health-related quality of life in children with neurodevelopmental disorders: a scoping review. Dev Med Child Neurol. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31225644 Accessed 8 Jul 2019.","DOI":"10.1111\/dmcn.14301"},{"key":"8110_CR21","doi-asserted-by":"publisher","unstructured":"Iragorri N, Spackman E. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis. Public Health Reviews. 2018;39(17). https:\/\/doi.org\/10.1186\/s40985-018-0093-8.","DOI":"10.1186\/s40985-018-0093-8"},{"issue":"3","key":"8110_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/21622965.2018.1427094","volume":"8","author":"Katherine Flannigan","year":"2018","unstructured":"Flannigan K, Gill K, Pei J, Andrew G, Rajani H, McFarlane A, et al. Deferred diagnosis in children assessed for fetal alcohol spectrum disorder. Appl Neuropsychol Child. 2018:1\u20130. https:\/\/doi.org\/10.1080\/21622965.2018.1427094.","journal-title":"Applied Neuropsychology: Child"},{"issue":"5","key":"8110_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/0272989X08315241","volume":"28","author":"DM Naimark","year":"2008","unstructured":"Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Mak. 2008;28(5):706\u201312. https:\/\/doi.org\/10.1177\/0272989X08315241.","journal-title":"Med Decis Mak"},{"issue":"2","key":"8110_CR24","first-page":"e223","volume":"15","author":"SK Clarren","year":"2008","unstructured":"Clarren SK, Lutke J. Building clinical capacity for fetal alcohol spectrum disorder diagnoses in western and northern Canada. J Popul Ther Clin Pharmacol. 2008;15(2):e223\u201337.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"4","key":"8110_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/acer.12349","volume":"38","author":"LN Bakhireva","year":"2014","unstructured":"Bakhireva LN, Leeman L, Savich RD, Cano S, Gutierrez H, Savage DD, et al. The validity of phosphatidylethanol in dried blood spots of newborns for the identification of prenatal alcohol exposure. Alcohol Clin Exp Res. 2014;38(4):1078\u201385. https:\/\/doi.org\/10.1111\/acer.12349.","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"8110_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1530-0277.2006.00131.x","volume":"30","author":"EM Ostrea Jr","year":"2006","unstructured":"Ostrea EM Jr, Hernandez JD, Bielawski DM, Kan JM, Leonardo GM, Abela MB, et al. Fatty acid ethyl esters in meconium: are they biomarkers of fetal alcohol exposure and effect? Alcohol Clin Exp Res. 2006 Jul;30(7):1152\u20139. https:\/\/doi.org\/10.1111\/j.1530-0277.2006.00131.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"8110_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1067\/S0022-3476(03)00442-6","volume":"143","author":"CF Bearer","year":"2003","unstructured":"Bearer CF, Jacobson JL, Jacobson SW, Barr D, Croxford J, Molteno CD, et al. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr. 2003;143(4):463\u20139. https:\/\/doi.org\/10.1067\/S0022-3476(03)00442-6.","journal-title":"J Pediatr"},{"issue":"3","key":"8110_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007691-200306000-00004","volume":"25","author":"D Chan","year":"2003","unstructured":"Chan D, Bar-Oz B, Pellerin B, Paciorek C, Klein J, Kapur B, et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Ther Drug Monit. 2003;25(3):271\u20138. https:\/\/doi.org\/10.1097\/00007691-200306000-00004.","journal-title":"Ther Drug Monit"},{"key":"8110_CR29","volume-title":"Meta-analysis: Fixed effect vs. random effects","author":"M Borenstein","year":"2007","unstructured":"Borenstein M, Hedges L, Rothstein H. Meta-analysis: Fixed effect vs. random effects. 2007. https:\/\/www.meta-analysis.com Accessed 28 Mar 2019."},{"key":"8110_CR30","unstructured":"LaFrance MA, McLachlan K, Nash K, Andrew G, Loock C, Oberlander TF, et al. Evaluation of the neurobehavioral screening tool in children with fetal alcohol spectrum disorders (FASD). J Popul Ther Clin Pharmacol. 2014;21(2):e197\u2013e210."},{"issue":"3","key":"8110_CR31","first-page":"e334","volume":"20","author":"P Breiner","year":"2013","unstructured":"Breiner P, Nulman I, Koren G. Identifying the neurobehavioral phenotype of fetal alcohol spectrum disorder in young children. J Popul Ther Clin Pharmacol. 2013;20(3):e334\u20139.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"3","key":"8110_CR32","first-page":"e440","volume":"18","author":"K Nash","year":"2011","unstructured":"Nash K, Koren G, Rovet J. A differential approach for examining the behavioural phenotype of fetal alcohol spectrum disorders. J Popul Ther Clin Pharmacol. 2011;18(3):e440\u201353.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"4","key":"8110_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00737-006-0130-3","volume":"9","author":"K Nash","year":"2006","unstructured":"Nash K, Rovet J, Greenbaum R, Fantus E, Nulman I, Koren G. Identifying the behavioural phenotype in fetal alcohol spectrum disorder: sensitivity, specificity and screening potential. Arch Womens Ment Health. 2006;9(4):181\u20136. https:\/\/doi.org\/10.1007\/s00737-006-0130-3.","journal-title":"Arch Womens Ment Health"},{"key":"8110_CR34","first-page":"e5","volume":"4","author":"B Stade","year":"2006","unstructured":"Stade B, Ungar WJ, Stevens B, Beyene J, Koren G. The burden of prenatal exposure to alcohol: measurement of cost. J FAS Int. 2006 Feb;4:e5.","journal-title":"J FAS Int"},{"issue":"1","key":"8110_CR35","first-page":"e108","volume":"22","author":"K McLachlan","year":"2015","unstructured":"McLachlan K, Andrew G, Pei J, Rasmussen C. Assessing FASD in young children: exploring clinical complexities and diagnostic challenges. J Popul Ther Clin Pharmacol. 2015;22(1):e108\u201324.","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"10022","key":"8110_CR36","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(15)01345-8","volume":"387","author":"S Popova","year":"2016","unstructured":"Popova S, Lange S, Shield K, Mihic A, Chudley AE, Mukherjee RA, Bekmuradov D, Rehm J. Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis. Lancet. 2016;387(10022):978\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(15)01345-8.","journal-title":"Lancet"},{"issue":"1","key":"8110_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13148-018-0439-6","volume":"10","author":"AA Lussier","year":"2018","unstructured":"Lussier AA, Morin AM, MacIsaac JL, Salmon J, Weinberg J, Reynolds JN, et al. DNA methylation as a predictor of fetal alcohol spectrum disorder. Clin Epigenetics. 2018;10(1):5. https:\/\/doi.org\/10.1186\/s13148-018-0439-6.","journal-title":"Clin Epigenetics"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-8110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-8110-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-8110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:13:15Z","timestamp":1608923595000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-8110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["8110"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-8110-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11956\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11956\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11956\/v2","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval is not required for model-based studies at the present study\u2019s institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1746"}}